Sarepta Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AB3A.F | DSGN | CAPR | STOK | IONS | TSHA | |
|---|---|---|---|---|---|---|
| Market cap | 1.76B | 665.24M | 518.60M | 1.78B | 6.67B | 1.42B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.9 | -6.6 | -6.1 | -7.3 | -35.0 | -9.4 |
| Price/book | 1.3 | 3.0 | 2.1 | 5.0 | 15.1 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +0.06% | +54.73% | +32.48% | +22.16% | −45.82% | +11.22% |
| Today | +2.34% | +2.80% | +8.25% | +1.70% | −0.67% | +6.60% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AB3A.F news ›Sarepta Therapeutics to Present at Upcoming Investor Conferences
HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) Celestica Announces Third Quarter 2026 Financial Results and Will Hold 2026 Investor and Analyst Day Quantum Cyber Invited…
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the…
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Sell-Side Analysts
Posted by Michael Walen on Oct 18th, 2026 Read Our Latest Research Report on Sarepta Therapeutics Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for…
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Details from the SRP-1003 poster presentation: P-066: Preclinical Evaluation of SRP-1003: An αvβ6 Integrin-Targeting siRNA Platform for Targeted Knockdown of DMPK in Myotonic Dystrophy Type 1 (C. Greer, et al.) SRP-1003 also reduced toxic…
Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $18.00. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Ultragenyx Pharmaceutical,…
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX). In a report released today, Anupam Rama from J.P.…
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright
Posted by Danessa Lincoln on Oct 6th, 2026 Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by equities researchers at HC Wainwright in a report released on Monday, MarketBeat.com reports. They…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com4
- theglobeandmail.com2
- defenseworld.net1
- markets.businessinsider.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.